RxDoctor Payments Data

Stephanie Grasky, PA

Medical · Tucson, AZNPI 1386833366

Payments from drug & device makers

$7,276in general payments, 2019–2025

Across 415 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$938
  • Amgen$682
  • AbbVie$563
  • Lilly USA, LLC$421
  • Abbott$312
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$7,276100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,276 in reported general payments places this provider in the 90th percentile of 748 medical providers in Arizona.

See all medical providers in Arizona

Medicare billing

Part B allowed, 2024
$85,260
Medicare patients
299
Services billed
1,682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$103,175
Trelegy ElliptaFluticasone/Umeclidin/Vilanter92$64,938
JardianceEmpagliflozin27$42,420
EliquisApixaban30$26,012
MounjaroTirzepatide16$25,439
XareltoRivaroxaban20$22,213
FarxigaDapagliflozin Propanediol11$15,628
Advair HfaFluticasone Propion/Salmeterol18$6,829
Breo ElliptaFluticasone/Vilanterol11$3,856
SymbicortBudesonide/Formoterol Fumarate14$3,564
Gabapentin131$3,391
Albuterol Sulfate HfaAlbuterol Sulfate109$3,297
Estradiol42$2,761
Levothyroxine Sodium277$2,675
Atorvastatin Calcium350$2,487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$148$103,17582 claims
GSKTrelegy Ellipta, Breo Ellipta$1,520$68,794103 claims
Boehringer IngelheimJardiance$116$42,42027 claims
PfizerEliquis$296$26,01230 claims
Lilly USA, LLCMounjaro$421$25,43916 claims
Johnson & JohnsonXarelto$159$22,21320 claims
AstraZenecaFarxiga, Symbicort$938$19,19225 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$2,675277 claims
AbbVieSynthroid$563$2,30536 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 748 medical providers in Arizona.

Other medical in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →